Japanese company profile · 4584

Kidswell Bio Corporation

In its FY2025 public filing, Kidswell Bio Corporation reports Pharmaceutical Development Business. The page shows business-level revenue and profit where the source disclosures support comparison.

Original Japanese company name: キッズウェル・バイオ株式会社

English company name recorded in Japan's EDINET filer data. English company name source

Reported company-wide figures

Company revenue: ¥6.59B ↗
Company profit: −¥138.51M ↗
Profit margin: -2.1% ↗

What does this company do?

Kidswell Bio Corporation's largest reported business by revenue in FY2025 was Pharmaceutical Development Business.

FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.

Business structure

How does it make money?

Business	Sales	Revenue share	Operating profit
Pharmaceutical Development Business	¥6.59B ↗	100.0%	−¥138.51M ↗

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.

Original Japanese label

Pharmaceutical Development Business: 医薬品開発事業
Sales: 売上高
Operating profit: 営業利益

Original Japanese label

Pharmaceutical Development Business: 医薬品開発事業
Sales: 売上高
Operating profit: 営業利益

Reported Sales by business over time

Fiscal year	FY2021	FY2024	FY2025
Pharmaceutical Development Business	¥1.57B	¥5.08B	¥6.59B

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

No comparable reported revenue growth is available.

What has changed?

Not disclosed or not safely comparable in the available filings.

Source

Public filing

FY2025 · fiscal year ended March 2026

The source document may be in Japanese.

Filing ID: S100YMXX

View original filing ↗

Ask about this company

The source document may be in Japanese.